Inactive Instrument

Other languages Avalanche Biotechnologies Inc Nasdaq

Equities

US05337G1076

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Adverum Biotechnologies Files $200 Million Mixed Shelf	Mar. 21
Adverum Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18
Adverum Biotechnologies, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 18
Adverum Biotechnologies, Inc. Announces Positive Preliminary Efficacy and Safety Data from Luna Phase 2 Trial of Ixo-Cov in Patients with Wet AMD	Feb. 08
4D Molecular soars as mid-stage data for eye disease therapy 'checks all boxes'	Feb. 05
Adverum Biotechnologies, Inc. Appoints Romuald Corbau as Chief Scientific Officer and Member of Executive Committee	Jan. 29
Adverum Biotechnologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
Adverum Biotechnologies, Inc. Appoints C. David Nicholson to the Board of Directors	Nov. 06
Adverum Biotechnologies Announces Three-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023	Nov. 04
Adverum Biotechnologies, Inc. Announces Positive Aflibercept Protein Level Data from the Luna Phase 2 Trial	23-09-26
Adverum Biotechnologies, Inc. Appoints R. Andrew Andy Ramelmeier as Chief Technology Officer	23-08-21
Sector Update: Health Care Stocks Steady Premarket Friday	23-08-11
Adverum Biotechnologies Completes Enrollment in Mid-Stage Wet AMD Trial, Narrows Q2 Loss	23-08-10
Adverum Biotechnologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Adverum Biotechnologies, Inc. Completes Enrollment of Phase 2 LUNA Trial in Wet AMD	23-08-10
Adverum Biotechnologies Says it Licensed Ray Therapeutics for Gene Therapy Platform	23-06-12
Insider Buy: Adverum Biotechnologies	23-06-09
Adverum Biotechnologies, Inc. Announces Resignation of Richard Beckman as Chief Medical Officer	23-05-25
Adverum Biotechnologies Presents Data on Intravitreal Gene Therapy Program for Eye Disease	23-05-18
Adverum Biotechnologies, Inc. Presents Nonclinical Data in Support of Ixo-vec’s Phase 2 Clinical Development at ASGCT 2023 Annual Meeting	23-05-18

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Avalanche Biotechnologies Inc Nasdaq

Equities

US05337G1076

Other languages

Filters